1. Home
  2. IMTX vs ENOV Comparison

IMTX vs ENOV Comparison

Compare IMTX & ENOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immatics N.V.

IMTX

Immatics N.V.

HOLD

Current Price

$9.89

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Logo Enovis Corporation

ENOV

Enovis Corporation

HOLD

Current Price

$21.65

Market Cap

1.6B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMTX
ENOV
Founded
N/A
1995
Country
Germany
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Fluid Controls
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.6B
IPO Year
N/A
2008

Fundamental Metrics

Financial Performance
Metric
IMTX
ENOV
Price
$9.89
$21.65
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
8
Target Price
$19.25
$48.13
AVG Volume (30 Days)
359.8K
1.1M
Earning Date
11-17-2025
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$99,445,031.00
$2,233,266,000.00
Revenue This Year
N/A
$9.22
Revenue Next Year
$19.39
$4.60
P/E Ratio
N/A
N/A
Revenue Growth
N/A
11.57
52 Week Low
$3.30
$21.00
52 Week High
$12.41
$47.26

Technical Indicators

Market Signals
Indicator
IMTX
ENOV
Relative Strength Index (RSI) 51.05 33.79
Support Level $9.38 $21.00
Resistance Level $10.10 $22.78
Average True Range (ATR) 0.51 1.03
MACD 0.02 -0.14
Stochastic Oscillator 47.97 13.96

Price Performance

Historical Comparison
IMTX
ENOV

About IMTX Immatics N.V.

Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.

About ENOV Enovis Corporation

Enovis Corp is a medical technology company that offers medical devices and services across the continuum of patient care, from injury prevention to joint replacement to rehabilitation after surgery, injury, or degenerative disease. Its reportable segments are Prevention & Recovery (P&R) and Reconstructive (Recon). The company generates the maximum revenue from the Prevention & Recovery segment, which includes products that are used to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports-related injuries. The Reconstructive segment provides a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and surgical productivity tools. Geographically, it derives key revenue from the U.S.

Share on Social Networks: